Article

Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4A and RASSF1A and induces lung cancer in A/J mice

Environmental Health Sciences Division, National Institute for Environmental Studies, Tsukuba, Ibaraki 305-8506, Japan.
Toxicological Sciences (Impact Factor: 4.48). 07/2006; 91(2):372-81. DOI: 10.1093/toxsci/kfj159
Source: PubMed

ABSTRACT Although inorganic arsenate (iAs(V)) or arsenite (iAs(III)) is clearly a human carcinogen, it has been difficult to produce tumors in rodents. In the present study, we orally administered iAs(V) to A/J mice to examine arsenic carcinogenicity in rodent. A/J mice (male, n = 120) assigned to four groups were given drinking water containing 0, 1, 10, and 100 ppm iAs(V) for 18 months. At the end of experiment, the complete lungs were removed and used for examining histopathology and extracting RNA and DNA. Epigenetic effects of iAs(V) on DNA methylation patterns of p16INK4a and RASSF1A genes were determined by methylation-specific polymerase chain reaction. Changes of p16INK4a and RASSF1A at mRNA and protein levels were examined by reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arsenic was accumulated dose dependently in the lung tissues of iAs(V)-exposed mice. Increase in lung tumor number and lung tumor size was observed in iAs(V)-exposed mice compared to the control. Histopathological examination showed that the rate of poorly differentiated lung adenocarcinoma was much higher in iAs(V)-exposed mice than in the control. Methylation rates appeared to be higher in a dose-related tendency in lung tumors from iAs(V)-exposed mice compared to the control. Lower or loss of p16INK4a and RASSF1A expression was found in lung tumors from iAs(V)-exposed mice, compared to that in nontumor lung tissues from both control and iAs(V)-exposed mice, and this reduced or lost expression was in accordance with hypermethylation of the genes. In conclusion, iAs(V) exposure increased lung tumor incidence and multiplicity in A/J mice. Epigenetic changes of tumor suppressor genes such as p16INK4a and RASSF1A are involved in the iAs(V)-induced lung carcinogenesis.

Download full-text

Full-text

Available from: Toshifumi Wakai, Feb 06, 2014
0 Followers
 · 
88 Views
 · 
47 Downloads
  • Source
    • "Arsenic exposure alters DNA methylation of genes involved in tumorigenesis (reviewed in Bailey and Fry, 2014a). Tumor suppressor genes that are methylated in response to arsenic exposure include CDKN2A (Davis et al., 2000), tumor protein 53 (TP53) (Mass and Wang, 1997; Davis et al., 2000), von Hippel–Lindau tumor suppressor (VHL) (Zhong and Mass, 2001), RASSF1A (Cui et al., 2006a), DAPK (Chai et al., 2007), and reversion-inducingcysteine-rich protein with kazal motifs (RECK) (Huang et al., 2011). DNA methylation of oncogenes in response to arsenic include cyclin D1 (CCND1) (Chen et al., 2004), estrogen receptor alpha (ER-α) (Chen et al., 2004; Waalkes et al., 2004) and members of the RAS family of small G-proteins such as HRAS and KRAS (Benbrahim-Tallaa et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Exposure to toxic metals poses a serious human health hazard based on ubiquitous environmental presence, the extent of exposure, and the toxicity and disease states associated with exposure. This global health issue warrants accurate and reliable models derived from the risk assessment process to predict disease risk in populations. There has been considerable interest recently in the impact of environmental toxicants such as toxic metals on the epigenome. Epigenetic modifications are alterations to an individual's genome without a change in the DNA sequence, and include, but are not limited to, three commonly studied alterations: DNA methylation, histone modification, and non-coding RNA expression. Given the role of epigenetic alterations in regulating gene and thus protein expression, there is the potential for the integration of toxic metal-induced epigenetic alterations as informative factors in the risk assessment process. In the present review, epigenetic alterations induced by five high priority toxic metals/metalloids are prioritized for analysis and their possible inclusion into the risk assessment process is discussed.
    Frontiers in Genetics 07/2014; 5:201. DOI:10.3389/fgene.2014.00201
  • Source
    • "In accordance with the major studies published to date [26, 27], our results showed that the incidence of positive RASSF1A expression decreased progressively in the normal mucosa, adenoma, and tumor tissues. The loss of RASSF1A protein expression was found to be more obvious in tumor tissues than in the nontumor tissues. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. The RAS-association domain family 1 A (RASSF1A) is a classical member of RAS effectors regulating cell proliferation and apoptosis. Loss of RASSF1A expression may shift the balance towards a growth-promoting effect without the necessity of activating K-ras mutations. Its potential association with K-ras mutations in colorectal cancer (CRC) is unclear. Methods. RASSF1A expression was examined in normal mucosa, adenoma, and tumor tissues of colon and rectum, respectively. We examined the association of RASSF1A expression, mutations of K-ras, and EGFR status in 76 primary CRCs. The relationship between clinicopathological characteristics and RASSF1A expression was also analyzed. Results. RASSF1A expression level decreased progressively in normal mucosa, adenoma and, tumor tissues, and the loss of RASSF1A expression occurred more frequently in tumor tissues. Of 76 primary CRCs, loss of RASSF1A expression and/or K-ras mutations were detected in 77% cases. Loss of RASSF1A expression was more frequent in K-ras wild-type than in mutation cases (63% versus 32%, P = 0.011). Conclusions. Our study indicates that loss of RASSF1A may be involved in pathogenesis of CRC, its expression was found predominantly in K-ras wild-type CRCs, suggesting that it may be another way of affecting RAS signaling, in addition to K-ras mutations.
    06/2013; 2013:976765. DOI:10.1155/2013/976765
  • Source
    • "Lung cancer cell models have also shown that arsenic exposure resulted in P53 promoter hypermethylation and subsequent transcriptional silencing of this gene [78]. Promoter hypermethylation of tumor suppressors CDKN2A and RASSF1A was also observed in lung tumors of mice exposed to inorganic arsenate [75]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Arsenic is a well-known human carcinogen, which potentially affects ~160 million people worldwide via exposure to unsafe levels in drinking water. Lungs are one of the main target organs for arsenic-related carcinogenesis. These tumors exhibit particular features, such as squamous cell-type specificity and high incidence among never smokers. Arsenic-induced malignant transformation is mainly related to the biotransformation process intended for the metabolic clearing of the carcinogen, which results in specific genetic and epigenetic alterations that ultimately affect key pathways in lung carcinogenesis. Based on this, lung tumors induced by arsenic exposure could be considered an additional subtype of lung cancer, especially in the case of never-smokers, where arsenic is a known etiological agent. In this article, we review the current knowledge on the various mechanisms of arsenic carcinogenicity and the specific roles of this metalloid in signaling pathways leading to lung cancer.
    Molecular Cancer 03/2013; 12(1):20. DOI:10.1186/1476-4598-12-20 · 5.40 Impact Factor
Show more